Search results

Found 5,185 pages
AUTHOR: Kevin Grogan

18 Feb 2015:

Ferring buys BioSET's orthobiologics

Ferring Pharmaceuticals has acquired the assets of the USA’s BioSurface Engineering Technologies (BioSET), including two Phase III-ready ‘orthobiologics’ designed to improve bone repair. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/ferring_buys_biosets_orthobiologics_971064

16 Jan 2014:

Actavis to pull out of China

Actavis will pull out of China because it is not "worth the aggravation", chief executive Paul Bisaro has told Bloomberg. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/actavis_to_pull_out_of_china_1001367

7 Apr 2009:

Cephalon to file Nuvigil for jet lag

Cephalon has presented promising late-stage data on Nuvigil, its follow-on from the blockbuster Provigil, which suggests that the drug can alleviate the symptoms of jet lag. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/cephalon_to_file_nuvigil_for_jet_lag_985131

27 May 2011:

Teva gets FDA OK for generic Combivir

Teva Pharmaceutical Industries has been granted the first approval to market a generic version of the HIV drug Combivir. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/teva_gets_fda_ok_for_generic_combivir_980970

3 Jun 2011:

Watson sued over generic Viagra

Watson Pharmaceuticals is being sued by Pfizer over its plans to market a generic version of the US giant's erectile dysfunction drug Viagra. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/watson_sued_over_generic_viagra_980937

27 Nov 2012:

XTL buys Teva's stake in Proteologics

XTL Biopharmaceuticals has bought a major stake in fellow Israeli drugmaker Proteologics from Teva Pharmaceutical Industries. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/xtl_buys_tevas_stake_in_proteologics_976154

27 Apr 2014:

Europe approves J&J diabetes combo Vokanamet

Regulators in Europe have given the green light to Johnson & Johnson's new diabetes therapy Vokanamet. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/europe_approves_j_and_j_diabetes_combo_vokanamet_1001869

12 Mar 2010:

Ipsen signs obesity deal with Rhythm

Ipsen has granted a licence to the USA’s Rhythm Pharmaceuticals to take over two of its metabolic disorders. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/ipsen_signs_obesity_deal_with_rhythm_981647

25 Jul 2013:

Recordati acquires Tunisia's Opalia

Recordati is buying a 90% stake in Opalia Pharma of Tunisia in a deal valued at 80 million dinar, or around 37 million euros. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/recordati_acquires_tunisias_opalia_1005440

15 Mar 2013:

Vanda pulls EU filing for schizophrenia drug

The European Medicines Agency says it has been notified by Vanda Pharmaceuticals of the USA that it wants to withdraw its application for the schizophrenia drug Fanaptum (iloperidone) intended to be used for the treatment of schizophrenia. - News -

by Kevin Grogan

https://www.pharmatimes.com/news/vanda_pulls_eu_filing_for_schizophrenia_drug_1004648